{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-087601","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2026-07-28T21:11:31+00:00","discovered_at":"2026-07-28T21:14:00.291722+00:00","generated_at":"2026-07-28T21:14:14.649744+00:00","sec_items":["1.01","2.01","2.02","3.02","3.03","5.01","5.02","5.03","5.05","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Yarrow Bioscience completes reverse merger with VYNE; Yarrow stockholders own 97% of combined company","bullets":["VYNE valued at $8.5M, Pre-Merger Yarrow at $272.9M; exchange ratio 0.7171 shares of new co per Yarrow share.","Pre-Merger Yarrow stockholders own ~97% of combined company; VYNE stockholders ~3%.","VYNE paid $17.3M cash dividend ($0.40242/share) to its stockholders prior to close.","New board and officers appointed: CEO Rebecca Frey, CFO Tyler Zeronda, and four other C-suite; board of six members.","Pre-Merger Yarrow raised $200M in total: $100M Series A preferred and $100M PIPE pre-closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-087601","json":"https://secwatch.observer/filing/0001104659-26-087601.json","markdown":"https://secwatch.observer/filing/0001104659-26-087601.md","text":"https://secwatch.observer/filing/0001104659-26-087601.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/0001104659-26-087601-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/tm2620687d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-28T21:14:14.649744+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"214fed20fa","claim":"Rebecca Frey was appointed as Chief Executive Officer at VYNE Therapeutics Inc..","evidence_excerpt":"the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/0001104659-26-087601-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"2a3c5e9bd2","claim":"Steven Ryder was appointed as Chief Medical Officer at VYNE Therapeutics Inc..","evidence_excerpt":"the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer, Steven Ryder, M.D. as the Company's Chief Medical Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/0001104659-26-087601-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"2ef835bbfa","claim":"David Domzalski resigned as President and Chief Executive Officer at VYNE Therapeutics Inc..","evidence_excerpt":"each of David Domzalski, VYNE’s President and Chief Executive Officer, Iain Stuart, Ph.D., VYNE’s Chief Scientific Officer, and Mutya Harsch, VYNE’s Chief Legal Officer and General Counsel, resigned as executive officers at the Closing and their employment was terminated effective July 27, 2026","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/0001104659-26-087601-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"3f4a377a4d","claim":"Mutya Harsch resigned as Chief Legal Officer and General Counsel at VYNE Therapeutics Inc..","evidence_excerpt":"each of David Domzalski, VYNE’s President and Chief Executive Officer, Iain Stuart, Ph.D., VYNE’s Chief Scientific Officer, and Mutya Harsch, VYNE’s Chief Legal Officer and General Counsel, resigned as executive officers at the Closing and their employment was terminated effective July 27, 2026","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/0001104659-26-087601-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Legal Officer and General Counsel"}],"fact_type":"executive_change"},{"claim_id":"4fef060357","claim":"Iain Stuart resigned as Chief Scientific Officer at VYNE Therapeutics Inc..","evidence_excerpt":"each of David Domzalski, VYNE’s President and Chief Executive Officer, Iain Stuart, Ph.D., VYNE’s Chief Scientific Officer, and Mutya Harsch, VYNE’s Chief Legal Officer and General Counsel, resigned as executive officers at the Closing and their employment was terminated effective July 27, 2026","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/0001104659-26-087601-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"5159f71a70","claim":"Tyler Zeronda was appointed as Chief Financial Officer at VYNE Therapeutics Inc..","evidence_excerpt":"the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/0001104659-26-087601-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"ab6c6ef3ae","claim":"Rachael Alford was appointed as Chief Operating Officer at VYNE Therapeutics Inc..","evidence_excerpt":"the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer, Steven Ryder, M.D. as the Company's Chief Medical Officer, Lori Payton, Ph.D. as the Company's Chief Development Officer and Rachael Alford, Ph.D. as the Company's Chief Operating Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/0001104659-26-087601-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"ce91cf5b4a","claim":"Lori Payton was appointed as Chief Development Officer at VYNE Therapeutics Inc..","evidence_excerpt":"the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer, Steven Ryder, M.D. as the Company's Chief Medical Officer, Lori Payton, Ph.D. as the Company's Chief Development Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/0001104659-26-087601-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Development Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}